Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 3/20 | 0.54 |
| ▸ | MC3R | P41968 | 3/20 | 0.54 |
| ▸ | MC5R | P33032 | 2/20 | 0.54 |
| ▸ | AGER | Q15109 | 3/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.48 |
| ▸ | CTSD | P07339 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL77425 | 1.00 | MC4R (0.54) | MC4RMC3RMC5RAGERMTNR1A | |
| SCHEMBL3370759 | 0.91 | AGER (0.55) | AGERMTNR1ACHRM2CHRM3OPRM1 | |
| SCHEMBL1700010 | 0.90 | MC4R (0.49) | MC4RMC3RMC5RAGERMTNR1A | |
| SCHEMBL17506917 | 0.90 | MC4R (0.49) | MC4RMC3RMC5RAGERMTNR1A | |
| SCHEMBL736913 | 0.85 | AGER (0.50) | MC4RMC3RMC5RAGERMTNR1A | |
| SCHEMBL736914 | 0.85 | AGER (0.50) | MC4RMC3RMC5RAGERMTNR1A | |
| SCHEMBL13275447 | 0.84 | OPRM1 (0.51) | AGERMTNR1ACHRM2CHRM3OPRM1 | |
| SCHEMBL2400009 | 0.84 | OPRM1 (0.51) | AGERMTNR1ACHRM2CHRM3OPRM1 | |
| SCHEMBL862071 | 0.84 | AGER (0.47) | MC4RMC3RMC5RAGERMTNR1A | |
| SCHEMBL2400012 | 0.84 | OPRM1 (0.51) | AGERMTNR1ACHRM2CHRM3OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4745129-A2 | COMPOUND HAVING CYCLIC STRUCTURE | Daiichi Sankyo Company, Limited (JP) | 2026-05-20 | — | — | EP | disclosed |
| EP-3682881-B1 | COMPOUND HAVING CYCLIC STRUCTURE | DAIICHI SANKYO CO LTD (JP) | 2026-04-01 | — | — | EP | disclosed |
| US-12297187-B2 | Compound having cyclic structure | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-05-13 | — | — | US | disclosed |
| US-20230331700-A1 | COMPOUND HAVING CYCLIC STRUCTURE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-10-19 | — | — | US | disclosed |
| US-11512067-B2 | Compound having cyclic structure | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-11-29 | — | — | US | disclosed |
| US-20200347030-A1 | COMPOUND HAVING CYCLIC STRUCTURE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-11-05 | — | — | US | disclosed |
| EP-3682881-A1 | COMPOUND HAVING CYCLIC STRUCTURE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-07-22 | — | — | EP | disclosed |
| US-8138339-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12297187-B2 | Compound having cyclic structure | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ECE1, IL1B | MC4R 1772/4885MC3R 1041/4885MC5R 842/4885 |
| US-20200347030-A1 | COMPOUND HAVING CYCLIC STRUCTURE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ECE1, IL1B | MC4R 1772/4885MC3R 1041/4885MC5R 842/4885 |
| US-11512067-B2 | Compound having cyclic structure | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ECE1, IL1B | MC4R 1772/4885MC3R 1041/4885MC5R 842/4885 |
| US-20230331700-A1 | COMPOUND HAVING CYCLIC STRUCTURE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ECE1, IL1B | MC4R 1772/4885MC3R 1041/4885MC5R 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.